Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies.
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2012
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 27 Apr 2012 Company (Novartis Pharmaceuticals Corporation) added in associations field as reported by ClinicalTrials.gov.
- 05 Apr 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 05 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.